Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 6/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17687379 | 0.81 | MEN1 (0.43) | GPR35CHRNA7NAMPTKIF18ABCL2L1 | |
| SCHEMBL16396338 | 0.78 | GPR35 (0.46) | GPR35PTPN2BCL2L1STING1 | |
| SCHEMBL17687352 | 0.76 | MRGPRX1 (0.33) | KAT6AKAT5CHRNA7KIF18ABRAF | |
| SCHEMBL16395966 | 0.73 | GPR35 (0.44) | GPR35PTPN2BCL2L1STING1 | |
| SCHEMBL16395994 | 0.72 | PTPN2 (0.36) | CHRNA7SCN9APTPN2NAMPTSTING1 | |
| SCHEMBL16395990 | 0.69 | MAPT (0.46) | PTPN2STING1 | |
| SCHEMBL34471930 | 0.67 | GPR35 (0.63) | GPR35CHRNA7PTPN2BCL2L1STING1 | |
| SCHEMBL17842813 | 0.67 | GPR35 (0.63) | GPR35CHRNA7PTPN2BCL2L1STING1 | |
| SCHEMBL16396914 | 0.65 | MAPT (0.44) | PTPN2ACLYSTING1 | |
| SCHEMBL19433206 | 0.64 | GPR35 (0.47) | GPR35PTPN2BCL2L1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | GPR35 2270/4885KAT6A 3022/4885KAT5 2178/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | GPR35 2270/4885KAT6A 3022/4885KAT5 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.